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Leptin  has  emerged  over  the  past  decade  as a key hormone  not  only  in energy  balance  regulation  but also
in  neuroendocrine  and  inﬂammatory  processes.  The  aim  of the  present  study  was  to  evaluate  whether
hyperleptinemia  deregulates  neuropeptides  during  weight  loss.  A total  of  86  post-pubertal  obese  adoles-
cents  (with  or  without  hyperleptinemia)  participated  in  one  year  of  interdisciplinary  weight  loss  therapy
(clinical,  nutritional,  psychological  and  exercise-related).  Adipokine  and  neuropeptide  concentrations
were  measured  by ELISA,  visceral  fat was measured  by  ultrasound  and body  composition  was  mea-
sured  by  pletismography.  The  hyperleptinemic  patients  presented  a lower  alpha-MSH  concentration
and  higher  NPY/AgRP  ratio  while  the adiponectin/leptin  (A/L)  ratio  was  lower  compared  with  the  non-
hyperleptinemic  group.  After therapy,  signiﬁcant  improvements  in  BM,  BMI,  body  fat  mass,  visceral  and
subcutaneous  fat,  HOMA-IR,  QUICKI,  total  cholesterol  and  triglycerides  were  observed  in  both  groups.
Indeed,  we observed  signiﬁcant  increases  in  adiponectin  and  A/L  as  well  as reductions  in leptin  and
NPY/AgRP  ratio  in  the  hyperleptinemic  group.  In the  stepwise  multiple  linear  regression  analysis  with
leptin  concentration  as the  dependent  variable,  -MSH  and  body  fat mass  (%)  were  the independent
predictors  to explain  leptin  concentration.  For  the  entire  group,  we  found  positive  correlations  between
leptinemia  and  BMI  and  body  fat mass  (%)  as  well  as  a negative  correlation  with  free  fat mass  (%) and
alpha-MSH.  Finally,  we  veriﬁed  negative  correlations  between  adiponectin/leptin  ratio  with  total  choles-
terol  and  LDL-c,  only  in  hyperleptinemic  patients.  In conclusion,  the hyperleptinemia  in obese  adolescents
s  durderegulates  neuropeptide
. Introduction
Leptin, an adipokine that is primarily expressed by adipose tis-
ue, is considered to be involved in neuroendocrine control of
nergy balance. However, in human obesity states of hyperleptine-
ia, central and peripheral leptin insensitivity is suggested. Indeed,
ecent studies showed that the hypothalamus is not leptin resis-
ant in hyperleptinemia conditions. Leptin deﬁciency results from
ecreased leptin transport across the blood brain barrier [18,27,29].
∗ Corresponding author at: Rua Professor Francisco de Castro, no 93, Vila
lementino  – São Paulo/SP, Postal Code: 04020-050, Brazil. Tel.: +55 11 5572 0177;
ax: +55 11 55720177.
E-mail address: ana.damaso@unifesp.br (A.R. Dâmaso).
196-9781 © 2011 Elsevier Inc. 
oi:10.1016/j.peptides.2011.04.025
Open access under the Elsevier OA license.ing  weight  loss.
© 2011  Elsevier  Inc.  
In the context of obesity and co-morbidities, states of hyper-
leptinemia began as an idea that the body’s biomolecular
milieu decreases overall sensitivity to leptin effects such that
normal or, classically, increased levels produce an inadequate
response [18,27]. This concept is reinforced by the observa-
tion that most obese individuals, including adolescents have
increased serum leptin concentrations, causing hyperleptinemia, as
recently demonstrated in the literature and by our research group
[24,27,43].
In a previous study, it was  demonstrated that the prevalence
of hyperleptinemia was 25.92% among obese adolescents [11] and
that 20% of postmenopausal women presented hyperleptinemia
Open access under the Elsevier OA license.[2]. Since its discovery more than a decade ago, leptin has been
established as a key regulator of energy balance [7,38]; however,
recent evidence indicates that leptin deﬁciency is a pivotal link in
obesity-related diseases [3,14].
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As mentioned above, hyperleptinemia is commonly observed
n obese humans and animals [4,42,45]. Inversely, a decrease in
diponectin concentration was demonstrated by several investi-
ations in obese adolescents and adults. However, the potential
echanisms for diminished adiponectinemia and hyperleptinemia
s related to inﬂammation remain to be investigated in obese ado-
escents [9,37].  Thus, the interplay among adipokines, leptin and
diponectin may  be an important contributor in the pathogenesis
f obesity and other co-morbidities.
In the central nervous system, NPY, AgRP and -MSH produced
y neurons in the hypothalamus act locally to regulate energy
alance. NPY exerts a physiologically important role in energy
omeostasis [25,41]. However, blood NPY levels will reﬂect its
ecretion from the adrenal gland, sympathetic nervous system and
dipocytes, which may  contribute to adiposity and its metabolic
onsequences [13,26].
-MSH exerts an important role in the energy balance in obese
dolescents; changes in expression were correlated to weight sta-
us changes [24,31].  However, previous authors did not investigate
his association with changes in leptin concentration, as related to
yperleptinemic status. Because the melanocortin (MC) system lies
ownstream of leptin sensitivity, it is important to understand this
nteraction during clinical weight loss intervention to optimize the
linical approach to improve energy balance as a key strategy for
besity control.
Several studies have shown a relationship between leptin lev-
ls and energy balance in obese youngsters; however, the results
re inconclusive, with leptin levels that either decrease or remain
nchanged after exercise or dietary intervention [5].
Therefore, the role of a long-term interdisciplinary weight loss
rogram on pro-anti-inﬂammatory pathways and the central reg-
lation of energy balance were analyzed in obese adolescents with
r without hyperleptinemia. The aims of the present study were to
nvestigate the role of hyperleptinemia during weight loss therapy
n energy balance in obese adolescents and to determine whether
 state of hyperleptinemia could adversely deregulate neuropep-
ides.
. Materials and methods
.1. Subjects
A total of 86 obese adolescents (39 boys and 47 girls) who
ntered the Interdisciplinary Obesity Program of the Federal Uni-
ersity of São Paulo – Paulista Medical School were assigned to two
ub-groups: hyperleptinemic (H) or non-hyperleptinemic (n-H).
hose who were considered hyperleptinemic presented baseline
alues above 20 ng/ml for boys and 24 ng/ml for girls, as based on
eference values cited by Gutin et al. [12] and Whatmore et al. [44].
hese patients were submitted to weight loss therapy. The evalu-
tions were performed at baseline, after 6 months and after 1 year
f an interdisciplinary approach.
The ages of the participants ranged from 15 to 19 years
16.6 ± 1.67 years). BMI  was 37.03 ± 3.78 kg/m2. All participants
ere conﬁrmed as meeting the inclusion criteria of post-pubertal
tage V [40] (based on the Tanner stages of obesity (BMI >95th
ercentile of the CDC reference growth charts)) [6].  Exclusion cri-
eria were identiﬁed genetic, metabolic or endocrine disease and
revious drug utilization. Informed consent was obtained from all
ubjects and/or their parents, including agreement of the adoles-
ents and their families to participate as volunteers. This study was
erformed in accordance with the principles of the Declaration of
elsinki and was formally approved by the Institutional Ethical
ommittee (#0135/04).32 (2011) 1384–1391 1385
2.2. Study protocol and medical screening
The subjects were medically screened; their pubertal stages and
their anthropometric measures were assessed (height, weight, BMI
and body composition). The endocrinologist completed a clinical
interview, including questions to determine eligibility based on
inclusion and exclusion criteria. A blood sample was collected and
analyzed, and ultrasound (US) was performed to measure visceral
and subcutaneous fat. All subjects underwent an ergometric test.
Indeed, the procedures were scheduled for the same time of day to
remove any inﬂuence of diurnal variations.
2.3. Anthropometric measurements and body composition
Subjects were weighed wearing light clothing and no shoes on
a Filizola scale to the nearest 0.1 kg. Height was  measured to the
nearest 0.5 cm by using a wall-mounted stadiometer (Sanny, model
ES 2030). BMI  was calculated as body weight divided by height
squared. Body composition was estimated by plethysmography in
the BOD POD body composition system (version 1.69, Life Measure-
ment Instruments, Concord, CA) [10].
2.4. Serum analysis
Blood samples were collected in the outpatient clinic around
8 h after an overnight fast. Insulin resistance was assessed by
the homeostasis model assessment-insulinesistance (HOMA-IR)
index and the quantitative insulin sensitivity check index (QUICKI).
HOMA-IR was calculated using the fasting blood glucose (FBG)
and immunoreactive insulin (I): [FBG (mg/dL) × I (mU/L)]/405;
QUICKI was calculated as 1/(log I + log FBG). Total cholesterol, TG,
HDL, LDL and VLDL were analyzed using a commercial kit (CELM,
Barueri, Brazil). The HOMA-IR data were analyzed according to ref-
erence values reported by Schwimmer et al. [35]. The a-MSH, NPY,
AgRP, total ghrelin, total adiponectin and leptin concentrations
were measured using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit from Phoenix Pharmaceuticals,
Inc. (Belmont, CA, USA) according to the manufacturer’s instruc-
tions. The coefﬁcient of variation (CV) for the adipokines and
neuropeptide procedure was  calculated: a-MSH (CV = 6.48%), NPY
(CV = 11.91%), AgRP (CV = 13.47%), ghrelin (CV = 6.82%), adiponectin
(CV = 4.5%) and leptin (CV = 4.07%). For this study, the leptin data
were analyzed according to reference values described by Gutin
et al. [12] and the ghrelin reference value adopted was 10–14 ng/ml.
according to Whatmore et al. [44].
2.5. Visceral and subcutaneous adiposity measurements
All abdominal ultrasonographic procedures and measurements
of visceral and subcutaneous fat tissue were performed by the
same physician, who was  blinded to subject assignment groups
at baseline and after intervention. This physician was  a special-
ist in imaging diagnostics. A 3.5-MHz multifrequency transducer
(broad band) was used to reduce the risk of misclassiﬁcation. The
intra-examination coefﬁcient of variation for ultrasound (US) was
0.8%.
US measurements of intra-abdominal (visceral) and subcuta-
neous fat were obtained. US-determined subcutaneous fat was
deﬁned as the distance between the skin and external face of the
rectus abdominis muscle, and visceral fat was deﬁned as the dis-
tance between the internal face of the same muscle and the anterior
wall of the aorta. Cut-off points to deﬁne visceral obesity by ultra-
sonographic parameters were based on previous methodological
descriptions by Ribeiro-Filho et al. [30].
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.6. Dietary program
Energy intake was set at the levels recommended by the dietary
eference intake for subjects with low levels of physical activity of
he same age and gender following a balanced diet [22]. No drugs
r antioxidants were recommended. Once a week, adolescents
ad dietetic lessons (providing information on the food pyramid,
iet record assessment, weight-loss diets and “miracle” diets, food
abels, dietetics, fat-free and low-calorie foods, fats (kinds, sources
nd substitutes), fast-food calories and nutritional composition,
ood nutritional choices on special occasions, healthy sandwiches,
hakes and products to promote weight loss, functional foods and
ecisions on food choices). All patients received individual nutri-
ional consultation during the intervention program.
At the beginning of the study and at 6 months and 12 months
nto the program, a 3-day dietary record was collected. Portions
ere measured in terms of familiar volumes and sizes. The dieti-
ian taught the parents and the adolescents how to record food
onsumption. These dietary data were transferred to a computer by
he same dietician, and the nutrient composition was  analyzed by a
oftware program developed at the Federal University of São Paulo
 Paulista Medical School (Nutwin version 1.5 for Windows, 2002)
hat used data from Western and local food tables. In addition, the
arents were encouraged by a dietician to call if they needed extra
nformation.
.7. Exercise program
During the 1-year interdisciplinary intervention period, adoles-
ents followed a personalized aerobic training program including
 60-min session three times a week (180 min/week) under the
upervision of an exercise physiologist. Each program was  devel-
ped according to the results of an initial oxygen uptake test for
erobic exercises (cycle-ergometer and treadmill). The intensity
as set at a workload corresponding to a ventilatory threshold of
 (50–70% of oxygen uptake test). At the end of 6 months, aero-
ic tests were performed to assess physical capacity, and physical
raining intensity was adjusted for each individual. During the aero-
ic sessions, adolescents were submitted to heart-rate monitoring.
he exercise program was  based on the 2001 recommendations
rovided by the American College of Sports Medicine [1].
.8. Psychological intervention
Diagnoses of common psychological problems associated with
besity, such as depression, disturbances of body image, anxiety
nd decreased self-esteem, were established by validated question-
aires. During the interdisciplinary intervention, the adolescents
ad weekly psychological support group sessions where they dis-
ussed body image and alimentary disorders, such as bulimia and
norexia nervosa, binge eating; their signs, symptoms and health
onsequences; the relationship between their feelings and food;
roblems in the family, such as alcoholism, and other topics. Indi-
idual psychological therapy was recommended when we found
ndividuals with nutritional and behavioral problems.
.9. Statistical analysis
All data were analyzed using STATISTICA version 6 for Win-
ows, with the signiﬁcance level set at p < 0.05. Data are
xpressed as the mean ± SD unless otherwise stated. Distribu-
ional assumptions were veriﬁed by the Kolmogorov–Smirnov test,
nd non-parametric methods were performed when appropriate.
dipokines and neuropeptides were analyzed with non-parametric
ests and expressed as median, minimum and maximum values.
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intervention were made using an analysis of variance (ANOVA)
for repeated measures or the Wilcoxon signed rank test of
non-parametric variables. Comparisons between groups were per-
formed using a one-way ANOVA or the Mann–Whitney test
(non-parametric variables). Pearson’s correlation was  performed
to test the direction and strength of the relationship between lep-
tin concentration and the variables of interest and to select those
variables that did not present collinearity, to select the predictors in
the multiple regression. Stepwise multiple linear regression anal-
ysis was performed to estimate the association with parameters
known to inﬂuence leptin concentration.
3. Results
At the beginning of therapy, 86 obese adolescents were enrolled
in the program. The results are presented for the whole population
studied: we  did not ﬁnd signiﬁcant gender differences in BMI  at
baseline. Indeed, the subjects were paired according to BMI, then
divided and analyzed according to leptinemic state.
3.1. Normoleptinemic patients
After weight loss intervention, we  observed signiﬁcant improve-
ments in BM,  BMI, body fat mass (% and kg), visceral and
subcutaneous fat, insulin concentration, HOMA-IR, QUICKI, total
cholesterol and triglycerides. Indeed, short- and long-term inter-
ventions increased the free fat mass (%) (Table 1 Table 1).
Based on the adipokine and neuropeptide data, we veriﬁed
increases in adiponectin concentration and adiponectin/leptin ratio
with a concomitant reduction in alpha-MSH concentration. The
leptin concentration decreased, while the orexigenic factors (ghre-
lin and AgRP) increased after 1 year. When we  analyzed the AgRP
from 6 months to 1 year of intervention, a signiﬁcant increase was
observed (Table 2 Table 2).
3.2. Hyperleptinemic patients
After weight loss intervention, we  observed signiﬁcant improve-
ments in BM,  BMI, body fat mass (% and kg), visceral and
subcutaneous fat, insulin concentration, HOMA-IR, QUICKI, total
cholesterol and triglycerides, similar to the trend observed in the
normoleptinemic patients. Only long-term (1 year) treatment was
able to promote a signiﬁcant increase in free fat mass (%) (Table 1).
The group with hyperleptinemia exhibited a signiﬁcant increase
in adiponectin, NPY concentration and adiponectin/leptin ratio as
well as a reduction in leptin and NPY/AgRP ratio with short-term
intervention. After one year, this group presented a signiﬁcant
increase in adiponectin/leptin ratio and in AgRP concentration,
with a reduction in the NPY/AgRP ratio (Table 2).
3.3. Comparison between the groups
It is important to note that hyperleptinemic patients presented
lower adiponectin/leptin ratio, alpha-MSH and ghrelin concentra-
tion at baseline. Indeed, the NPY/AgRP ratio was higher compared
with that observed in the non-hyperleptinemic group.
We found positive correlations between leptin concentrations
and BMI  and body fat mass (%) at baseline, in the entire group
(Fig. 1a and b). On the other hand, the leptin concentrations were
negatively correlated with free fat mass (%) and alpha-MSH (Fig. 2a
and b). Negative correlations between adiponectin/leptin ratio and
total cholesterol and LDL-c were conﬁrmed at baseline only in
hyperleptinemic patients (Fig. 3a and b).
As shown in Table 3 Table 3, stepwise multiple linear regression
analysis was  performed with leptin concentration as the depen-
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Fig. 1. Positive correlation between leptin concentration with BMI  (a) and body fat (%) (b) at baseline conditions in the entire group.
Fig. 2. Negative correlation between leptin concentrations with free fat mass (%) (a) and alpha-MSH (b) at baseline conditions in the entire group.
Fig. 3. Negative correlations between adiponectin/leptin ratio with cholesterol total (a) and LDL-c (b) in hyperleptinemic patients at baseline conditions.
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Table  3
Multiple regression analysis for the leptin concentration in the entire group.
Leptin
Regression coefﬁcient  ˇ p
Age 0.08 0.29
Alpha-MSH (ng/ml) −0.47 0.001
Body fat mass (%) −0.33 0.001
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nVisceral fat (cm) −0.04 0.60
Subcutaneous fat (cm) 0.08 0.39
ent variable. -MSH and body fat mass (%) were the independent
redictors to explain leptin concentration in the present study.
. Discussion
Obesity has been shown to cause resistance or reduced sensi-
ivity to several hormones, including leptin and adiponectin. Obese
ndividuals appear to have higher sympathetic nervous system
SNS) activity; however, the metabolic response to SNS stimula-
ion appears reduced in this population. This ﬁnding suggests that,
n obesity, any compensatory effect of the SNS on metabolism to
ncrease energy expenditure may  not occur, rendering weight loss
ore difﬁcult [8,33].
We  veriﬁed that, after the therapy, obese adolescents have
ecreased body weight, total body fat, visceral fat and leptin con-
entration; however, some of them remain in a hyperleptinemic
tate (Table 1).
Studies have reported hyperleptinemia in insulin-resistant indi-
iduals independently of the level of obesity. Indeed, they reported
ross-sectional associations between hyperleptinemia and insulin
esistance independently of body mass index in a population-based
ohort. These studies indicate that leptin and insulin are involved
n a complex regulatory loop and highlight the pivotal role of leptin
n glucose homeostasis, acting as an insulin sensitizer when leptin
evels are at low and normal levels and possibly contributing to
nsulin resistance when leptin is chronically elevated [32,36].
In addition, in the non-hyperleptinemic group, there was a sig-
iﬁcant increase in free fat mass (%) after short-term therapy. In
he hyperleptinemic patients, this increase occurred after only one
ear of intervention. In fact, evidence derived from animal and
uman studies suggests that the ability of leptin and adiponectin to
timulate fat acid (FA) oxidation in muscle is impaired in obesity.
hus, leptin deﬁciency and adiponectin resistance may  be initiat-
ng factors in the accumulation of intramuscular lipids. This ﬁnding
ay  partially explain why the fat free mass (%) was signiﬁcantly
ncreased only after long-term intervention in the hyperleptinemic
roup [8].
In the present study, hyperleptinemic patients presented higher
alues of orexigenic factors. This fact suggests that the leptinemic
tate affects the neuroendocrine energetic balance, stimulating the
rexigenic pathways, which make weight loss difﬁcult in obese
dolescents.
One of the most important ﬁndings in the present investigation
as the lower alpha-MSH concentration at baseline, which was
aintained after weight loss in the volunteers with hyperleptine-
ia  (Table 2). We  also showed that at baseline, leptin concentration
as negatively correlated with alpha-MSH, reinforcing the concept
hat a disruption between the mechanisms involved in energy bal-
nce occurs in obese adolescents, rendering weight loss difﬁcult
nd ultimately predisposing these individuals to weight regain [33].
However, at the end of therapy, alpha-MSH was similar in both
nalyzed groups. In addition, we veriﬁed that the hyperleptinemia
ecreased signiﬁcantly after weight loss intervention, suggesting
he important role of this type of therapy in providing superior
euroendocrine regulation of energy balance.32 (2011) 1384–1391 1389
Animal experiments recently showed that the complexity of
melanocortin (MC) system effects varies with the nutritional state
and that responsiveness to the effects of alpha-MSH may  be main-
tained even in leptin-resistant animals, suggesting that the MC
system (receptors and post-receptor signal transduction pathways)
is operant even in the absence of leptin input [33]. Similarly, in mul-
tiple regression analyses, alpha-MSH was  a negative independent
predictor of leptin concentration (Table 3).
Therefore, it is necessary to conﬁrm these ﬁndings in different
populations because age-related obesity in the long-term regula-
tion of body weight is known to be associated with leptin resistance
[34,39] and alterations in body weight and composition. These ﬁnd-
ings may  be, at least partly, caused by changes in the activity of
anorexigenic and orexigenic neurohumoral systems. Components
of the MC  system in the hypothalamus are considered to be major
players in the regulation of energy metabolism and body weight
[28].
In agreement with the literature, we observed that in hyper-
leptinemic status, the ghrelin concentration was lower during the
intervention in comparison with the non-hyperleptinemic group.
An increase in ghrelin concentration at the end of therapy was
observed only in the non-hyperleptinemic patients. Such a change
is considered as an adaptive function of ghrelin in response to neg-
ative energy balance [7].  These data reinforce the concept of leptin
resistance in leptin excess status, as observed in obesity, as it was
previously demonstrated that leptin inhibits ghrelin efﬂux from the
stomach and reduced ghrelin-induced feeding [15,21,23].
Important evidence in the present investigation is that the
NPY/AgRP ratio was signiﬁcantly higher at baseline in the hyper-
leptinemic group. This ﬁnding could be explained by impaired
leptin function in maintaining energy homeostasis, restraining the
release of NPY, in the hyperleptinemia group [15]. However, both
groups presented a reduction of this ratio in the course of weight
loss therapy, showing similar values at the end of the interven-
tion. These data reinforce the role of circulating levels of these
peptides in energy homeostasis in obese adolescents. Previously, it
was demonstrated that NPY and leptin form a loop system respon-
sible for providing feedback to the central nervous system on the
state of the peripheral energy stores. The suggested mechanism
includes nitric oxide-mediated regulation of leptin and NPY during
food intake in mice [19,20]. However, these mechanisms need to
be fully investigated in humans in future research efforts.
Recent studies showed that elevated circulating NPY levels and
leptin were observed in patients with cardiovascular diseases, such
as acute myocardial infarction, angina pectoris, heart failure and
hypertension where sympathetic nerve activity is increased, indi-
cating the clinical importance of NPY in regulating vessel function
[16,26]. Moreover, the interactions between NPY and the release of
inﬂammatory cytokines, such as leptin, in an atherosclerotic milieu
may  play a major role in the cardiovascular system [26].
Adiponectin levels improved signiﬁcantly after short- and
long-term therapies in the normoleptinemic group; however, the
hyperleptinemic patients showed an increase in this variable only
after long-term therapy. The slight change in adiponectin levels
could be linked to the time of intervention and may not be sufﬁcient
for detection. In a study with obese children, after lifestyle inter-
vention, adiponectin levels, together with several other metabolic
parameters, were signiﬁcantly improved, potentially due to weight
loss, improvement of metabolic status, or both [5].
Leptin and adiponectin are involved in the regulation of
metabolic homeostasis and inﬂammatory process in a constellation
of chronic diseases. Several studies have reported the association
of adipokines, especially A/L ratio, with the presence of metabolic
syndrome [14,17,46].  In agreement, Jung et al. [14] showed in adults
that the A/L ratio was  decreased in the presence of metabolic syn-
drome (MS) and that changes are related to the number of MS
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omponents. Our study corroborated these ﬁndings, revealing a
egative correlation between the A/L ratio and total cholesterol and
DL cholesterol in the hyperleptinemic group.
Thus, one important ﬁnding from the present study is that the
/L ratio was signiﬁcantly lower throughout the intervention in
hose with hyperleptinemia compared with non-hyperleptinemic
atients. However, weight loss therapy was effective in improving
his ratio in both analyzed groups.
Our study presented some limitations, such as a reduced number
f subjects, and we measured total ghrelin rather than acyl ghrelin,
lthough the acylation of this peptide is necessary to cross the blood
rain barrier to release GH and exert others endocrine functions.
However, we  demonstrate in obese adolescents that the A/L
atio was negatively correlated with total cholesterol and LDL
holesterol and higher values of NPY/AgRP in hyperleptinemic
atients. All together, these data reinforce the role of hyperleptine-
ia  in the deregulation of energy balance in obese adolescents,
uggesting that this pivotal interplay of leptin in energy balance
nd inﬂammation needs to be considered in a clinical intervention.
. Conclusions
In conclusion, our study reveals that long-term interdisciplinary
herapy promotes signiﬁcant improvement in the disruption of
omeostatic cross-talk between the afferent hormonal signals from
he periphery and the hypothalamic network of NPY, observed
ainly in hyperleptinemic obese patients. Finally, these data
an elucidate the interplay between hyperleptinemic status and
ncreased NPY/AgRP ratio with a concomitant decrease in alpha-
SH, factors implicated in impaired weight loss control.
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